JIPOAd
ESID
  • Users Online: 206
  • Print this page
  • Email this page
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Most cited articles *

 
 
  Archives   Most popular articles   Most cited articles
 
Show all abstracts  Show selected abstracts  Export selected to
  Cited Viewed PDF
EDITORIAL
Being realistic and optimistic in curing cancer
Aung Naing
October-December 2018, 1(2):53-55
DOI:10.4103/JIPO.JIPO_20_18  
  4 1,976 407
ORIGINAL ARTICLE
The Study of Druggable Targets in Nonsquamous Non-Small-Cell Lung Cancer in the Middle East and North Africa
Abdul Rahman Jazieh, Adda Bounedjar, Fouad Al Dayel, Shamayel Fahem, Arafat Tfayli, Kakil Rasul, Hassan Jaafar, Mohammad Jaloudi, Turki Al Fayea, Hatim Q Al Maghrabi, Hanaa Bamefleh, Khaled Al Kattan, Blaha Larbaoui, Taha Filali, Hamed Al Husaini, Yosra Ali, in collaboration with the Arab Collaborative Hematology Oncology Group (ACHOG)
January-March 2019, 2(1):4-7
DOI:10.4103/JIPO.JIPO_22_18  
  2 1,373 89
ORIGINAL ARTICLES
The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients' outcomes
Hamzah Abu-Sbeih, Tenglong Tang, Faisal Shaukat Ali, Daniel Hartman Johnson, Wei Qiao, Adi Diab, Yinghong Wang
July-September 2018, 1(1):7-18
DOI:10.4103/JIPO.JIPO_12_18  
  1 1,459 224
REVIEW ARTICLE
Extracellular signal-regulated kinase (ERK) inhibitors in oncology clinical trials
Haelee M Chin, David K Lai, Gerald S Falchook
January-March 2019, 2(1):10-16
DOI:10.4103/JIPO.JIPO_17_18  
  1 911 160
REVIEW ARTICLES
Cardiotoxicity of FDA-approved immune checkpoint inhibitors: A rare but serious adverse event
Abdulrazzak Zarifa, Mohammed Salih, Juan Lopez-Mattei, Hun Ju Lee, Cezar Iliescu, Saamir Hassan, Nicolas Palaskas, Jean-Bernard Durand, Elie Mouhayar, Joseph Kim, Peter Kim
October-December 2018, 1(2):68-77
DOI:10.4103/JIPO.JIPO_15_18  
  1 1,631 219
Should we design clinical trials differently in the era of cancer immunotherapy?
Chia-Chi Lin
April-June 2019, 2(2):36-39
DOI:10.4103/JIPO.JIPO_5_19  
  1 542 87
* Source: CrossRef